Detecting treatment emergent adverse events in clinical trials: A comparison of spontaneously reported and solicited collection methods

Drug Safety

Volumn 28, Issue 11, 2005, Pages 1057-1063

  Wernicke, Joachim F ^a   Faries, Douglas ^a   Milton, Denái ^a   Weyrauch, Karen ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; APPETITE DISORDER; ARTICLE; CALCULATION; CLINICAL TRIAL; COLD; CONSTIPATION; DIARRHEA; DIZZINESS; DREAM; DROWSINESS; DRUG EFFECT; HEADACHE; HEART PALPITATION; HUMAN; INFORMATION PROCESSING; INSOMNIA; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; RHINITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH DISEASE; STOMACH PAIN; TREMOR; XEROSTOMIA;

EID: 26944489067     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200528110-00006     Document Type: Article

References (12)

1. National Institute of Mental Health (NIMH). STESS: Subjective Treatment Emergent Symptoms Scale. Psychopharmacology Bulletin Vol 21 (Issue No. 4). Rockville (MD): National Institute of Mental Health, 1985: 1073-5
2. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86 (2): 184-92
3. Stieglitz RD, Fahndrich E, Helmchen H. The AMDP system. In: Mezzich JE, von Cranach M, editors. The international classification in psychiatry: unity & diversity. New York: Cambridge University Press, 1988: 180-204
4. Levine J, Schooler NR. Strategies for analyzing side effect data from SAFTEE: a workshop held fall 1985 in Rockville, Maryland. Psychophamacol Bull 1986; 22 (2): 343-81
5. Rabkin JG, Markowitz JS, Ocepek-Welikson K, et al. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol 1992; 12 (1): 3-9
6. Levine J, Schooler NR. General versus specific inquiry with SAFTE [letter]. J Clin Psychopharmacol 1992; 12 (6): 448
7. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Paediatrics 2001; 108 (5): e83
8. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53 (2): 112-20
9. Data on file (unpublished), Eli Lilly and Company
10. US Department of Health and Human Services. Coding symbols for thesaurus of adverse reaction terms. 3rd ed. Rockville (MD): Department of Health and Human Services, Food and Drug Administration, Center for Drug and Biologics, Division of Drug and Biological Experience, 1995
11. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20 (2): 109-17
12. Chernick MR. Bootstrap methods: a practitioner's guide. New York: John Wiley & Sons Inc., 1999: 53